# Genomics & Precision Medicine

**Connect your genomic data to targeted treatments and clinical trials.**

MyTreatmentPath's precision medicine dashboard links genomic mutations to evidence-based interventions, helping you understand **why** specific treatments target **your tumor's** vulnerabilities.

---

## Overview

The genomics system:
- ✅ Tracks mutations from Foundation One, Tempus, Caris, etc.
- ✅ Explains clinical significance of each mutation
- ✅ Recommends targeted therapies based on your profile
- ✅ Links supplements to specific genomic pathways
- ✅ Shows drug-gene interactions
- ✅ Finds clinical trials matching your mutations

---

## Adding Genomic Data

### From Foundation One Report

1. Go to **Genomics** → **Mutations**
2. Click **"+ Add Mutation"**
3. Enter mutation details:
   - **Gene:** e.g., `FGFR3`, `ARID1A`, `PIK3CA`
   - **Variant Type:** Activating, Loss of Function, etc.
   - **Clinical Significance:** Driver, Resistance, etc.
   - **Allele Frequency:** If reported (e.g., 45%)

### Supported Mutation Types

**Activating Mutations** (gain of function):
- FGFR3 - Drives cell proliferation
- PIK3CA - Activates survival pathways
- KRAS - Promotes growth signaling

**Loss of Function** (tumor suppressors):
- ARID1A - Chromatin remodeling, immune evasion
- PTEN - Suppresses PI3K pathway
- TP53 - "Guardian of the genome"

### What Gets Stored

- ✅ **Local encrypted database** - Genomic data is PHI, stays local
- ✅ **Mutation-treatment mappings** - AI links mutations to interventions
- ❌ **Never synced to cloud** - Too sensitive

---

## Precision Medicine Dashboard

Access: **Genomics** tab in main app

### Mutations View

See all your mutations with:
- Gene name + variant type
- Clinical significance
- Pathways affected
- Targetable with (drugs/supplements)
- Evidence level (FDA approved, clinical trial, preclinical)

### Therapeutic Pathways

System groups mutations by affected pathways:

**1. Hypoxia/HIF1 Signaling** (Cancer stem cells)
- **Mutations:** ARID1A loss
- **Targets:** Artemisinin, Ivermectin, Fenbendazole
- **Mechanism:** Disrupt hypoxic niches where stem cells hide

**2. MDR/Drug Resistance** (Chemo resistance)
- **Mutations:** PIK3CA activation
- **Targets:** Berberine, Curcumin, Quercetin
- **Mechanism:** Reverse P-glycoprotein drug pumps

**3. PD-L1 Immune Escape**
- **Mutations:** ARID1A loss (increases PD-L1)
- **Targets:** Keytruda (pembrolizumab), Bavencio
- **Mechanism:** Block PD-1/PD-L1 checkpoint

**4. PI3K/AKT/mTOR** (Survival pathway)
- **Mutations:** PIK3CA activation, PTEN loss
- **Targets:** Green Tea (EGCG), Metformin, Rapamycin
- **Mechanism:** Inhibit downstream survival signals

**5. FGFR Signaling** (Proliferation)
- **Mutations:** FGFR3 activation
- **Targets:** Erdafitinib, BGJ398
- **Mechanism:** Block FGFR tyrosine kinase

---

## Medication Recommendations

Based on your genomic profile, the system suggests:

### Chemotherapy Compatibility
- **GOOD:** Gemcitabine + Cisplatin (if ERCC1 low)
- **POOR:** Taxanes (if MDR1 overexpressed due to PIK3CA)

### Targeted Therapies
- **FGFR inhibitors** (if FGFR3 mutated)
- **PI3K inhibitors** (if PIK3CA mutated)
- **Immune checkpoint inhibitors** (if ARID1A loss → high PD-L1)

### Supplements (Evidence-Based)
- **Artemisinin** → Targets HIF1α (ARID1A-driven stem cells)
- **Berberine** → Reverses MDR pumps (PIK3CA-driven resistance)
- **Curcumin** → Inhibits PI3K/mTOR
- **Green Tea (EGCG)** → Modulates PI3K signaling
- **Quercetin** → Antioxidant + MDR reversal

---

## Clinical Trials Matching

System finds trials based on:
- **Mutations:** FGFR3+, PIK3CA+, ARID1A-
- **Cancer type:** Bladder, urothelial, genitourinary
- **Phase:** I/II/III (prefer II+ for efficacy data)
- **Status:** Recruiting, Active

**Example matches:**
- **Erdafitinib** (FGFR inhibitor) - FDA approved for FGFR3+ bladder cancer
- **BT8009** (Bicycle Toxin Conjugate) - Targets Nectin-4 (all bladder cancers)
- **PI3K/mTOR inhibitors** - For PIK3CA+ tumors

---

## Understanding Your Report

### Example: ARID1A Loss of Function

**What it does:**
- Chromatin remodeling gene that normally suppresses cancer stem cells

**Impact of loss:**
- ✅ Promotes cancer stem cell phenotype (treatment-resistant)
- ✅ Enhances HIF1 signaling (hypoxic niches)
- ✅ Increases PD-L1 expression (immune evasion)

**Clinical significance:**
- ⚠️ Makes tumors more resistant to chemotherapy
- ✅ But also more immunogenic (better response to Keytruda!)

**Targeted interventions:**
- Artemisinin (targets HIF1α-driven stem cells)
- Ivermectin (disrupts hypoxic niches)
- Keytruda (anti-PD-1 immunotherapy)

---

## Evidence Levels

System shows evidence strength for each recommendation:

**Level 1: FDA Approved**
- Erdafitinib for FGFR3+ bladder cancer
- Keytruda for PD-L1+ tumors

**Level 2: Clinical Trials (Phase II+)**
- BT8009 (Nectin-4 targeting)
- Enfortumab vedotin (Padcev)

**Level 3: Preclinical (Cell/Animal Studies)**
- Artemisinin for cancer stem cells
- Berberine for MDR reversal
- Fenbendazole for microtubule disruption

**Level 4: Mechanistic (Pathway-based)**
- Green tea EGCG for PI3K modulation
- Quercetin for antioxidant support

---

## Drug-Gene Interactions

System flags interactions:

**PIK3CA Mutation:**
- ⚠️ **Caution:** Taxanes (paclitaxel) - MDR1 upregulation may reduce efficacy
- ✅ **Synergy:** Gemcitabine + Berberine (MDR reversal)

**ARID1A Loss:**
- ✅ **Enhanced:** Keytruda (PD-L1 upregulation = better response)
- ⚠️ **Reduced:** Conventional chemo (stem cell phenotype)

---

## Integration with Medications

When you add a medication in **Treatment** → **Medications**, the system:
1. Checks genomic compatibility
2. Shows evidence for YOUR mutations
3. Flags potential interactions
4. Suggests dosing considerations

**Example:**
- Add "Artemisinin 200mg 2x/day"
- System shows: "Targets HIF1α hypoxia pathway (ARID1A loss)"
- Evidence: 4 peer-reviewed studies
- Synergy: Combines well with Ivermectin

---

## Privacy & Security

- ✅ **Encrypted at rest:** AES-256 encryption
- ✅ **Never synced to cloud:** Genomic data is PHI, stays local
- ✅ **No third parties:** No data sharing, ever
- ✅ **You own your data:** Export anytime

---

## Limitations

**This is NOT:**
- ❌ Medical advice (consult your oncologist)
- ❌ A replacement for genetic counseling
- ❌ FDA-reviewed treatment recommendations

**This IS:**
- ✅ Educational tool to understand your mutations
- ✅ Research aggregator for evidence-based interventions
- ✅ Conversation starter with your care team
- ✅ Decision support (not decision-making)

---

## Next Steps

1. **Upload your genomic report** (Foundation One, Tempus, Caris)
2. **Review mutation analysis** in Genomics dashboard
3. **Check medication compatibility** in Treatment → Medications
4. **Explore clinical trials** matching your profile
5. **Discuss with oncologist** - bring your report!

---

## References

See [Medication Evidence](medications.md) for peer-reviewed studies supporting each recommendation.

**Key sources:**
- Foundation Medicine reports
- NCCN Guidelines (bladder cancer)
- ClinicalTrials.gov
- PubMed (genomic-driven interventions)
- OncoKB (precision oncology database)

---

**Questions?** See [API Reference](../development/api-reference.md) for genomic data schema.
